Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315703068> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4315703068 endingPage "146.e22" @default.
- W4315703068 startingPage "146.e13" @default.
- W4315703068 abstract "We sought to quantify mCRPC patient treatment patterns and survival across multiple lines of therapy after prior androgen-receptor-axis-targeted therapy (ARAT) failure. Individuals diagnosed with prostate cancer between 2010 and 2018 were identified in the Ontario Cancer Registry (OCR). An algorithm was created to identify patients with mCRPC that was aligned to Prostate Cancer Clinical Trials Working Group 3 criteria (PCWG3) and validated with Canadian clinical experts. In the mCRPC setting, treatment patterns were assessed by line of therapy, and survival was calculated from treatment initiation until death or lost to follow-up. 64,484 men were diagnosed withprostate cancer in Ontario between 2010 and 2018with 5,588 men assessed to have mCRPC and 2,970 (53%) of those received first-line systemic treatment. Across the first-, second- and third-line of therapy, ARATs (abiraterone and enzalutamide) were the most used therapies. Survival for mCRPC patients treated with ARATs in first-, second- and third-line were 13.0 (95% CI, 11.6 – 14.5), 11.5 (95% CI, 10.1 – 13.4) and 8.9 (95% CI, 7.4 – 10.2) months, respectively. Survival for mCRPC patients treated with taxanes in first, second- and third-line were 16.7 (95% CI, 14.8 – 18.0), 11.3 (95% CI, 10.1 – 12.5) and 7.8 (95% CI, 6.5 – 10.6) months, respectively. No statistical difference in overall survival was found between taxanes and ARATs. In this analysis of a large retrospective cohort of Canadian men with mCRPC, we found that survival in patients treated with ARATs and taxanes was fairly similar across all lines of therapy. Importantly, this trend was maintained in ARAT-exposed patients, where sequential ARAT and taxanes offered similar survival. These data may help inform optimal sequencing of therapies in mCRPC." @default.
- W4315703068 created "2023-01-12" @default.
- W4315703068 creator A5021202830 @default.
- W4315703068 creator A5021347384 @default.
- W4315703068 creator A5021578362 @default.
- W4315703068 creator A5039128428 @default.
- W4315703068 creator A5079676031 @default.
- W4315703068 creator A5083304645 @default.
- W4315703068 date "2023-03-01" @default.
- W4315703068 modified "2023-10-16" @default.
- W4315703068 title "A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 – 2018" @default.
- W4315703068 cites W2151964152 @default.
- W4315703068 cites W2278392405 @default.
- W4315703068 cites W2908857416 @default.
- W4315703068 cites W2977469640 @default.
- W4315703068 cites W2999047517 @default.
- W4315703068 cites W3031249193 @default.
- W4315703068 cites W3087416729 @default.
- W4315703068 cites W3203391087 @default.
- W4315703068 cites W3215258031 @default.
- W4315703068 doi "https://doi.org/10.1016/j.urolonc.2022.11.019" @default.
- W4315703068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36641303" @default.
- W4315703068 hasPublicationYear "2023" @default.
- W4315703068 type Work @default.
- W4315703068 citedByCount "0" @default.
- W4315703068 crossrefType "journal-article" @default.
- W4315703068 hasAuthorship W4315703068A5021202830 @default.
- W4315703068 hasAuthorship W4315703068A5021347384 @default.
- W4315703068 hasAuthorship W4315703068A5021578362 @default.
- W4315703068 hasAuthorship W4315703068A5039128428 @default.
- W4315703068 hasAuthorship W4315703068A5079676031 @default.
- W4315703068 hasAuthorship W4315703068A5083304645 @default.
- W4315703068 hasConcept C10515644 @default.
- W4315703068 hasConcept C121608353 @default.
- W4315703068 hasConcept C126322002 @default.
- W4315703068 hasConcept C143998085 @default.
- W4315703068 hasConcept C167135981 @default.
- W4315703068 hasConcept C2776421732 @default.
- W4315703068 hasConcept C2776551883 @default.
- W4315703068 hasConcept C2778527826 @default.
- W4315703068 hasConcept C2780192828 @default.
- W4315703068 hasConcept C2781190966 @default.
- W4315703068 hasConcept C535046627 @default.
- W4315703068 hasConcept C61367390 @default.
- W4315703068 hasConcept C71924100 @default.
- W4315703068 hasConcept C72563966 @default.
- W4315703068 hasConceptScore W4315703068C10515644 @default.
- W4315703068 hasConceptScore W4315703068C121608353 @default.
- W4315703068 hasConceptScore W4315703068C126322002 @default.
- W4315703068 hasConceptScore W4315703068C143998085 @default.
- W4315703068 hasConceptScore W4315703068C167135981 @default.
- W4315703068 hasConceptScore W4315703068C2776421732 @default.
- W4315703068 hasConceptScore W4315703068C2776551883 @default.
- W4315703068 hasConceptScore W4315703068C2778527826 @default.
- W4315703068 hasConceptScore W4315703068C2780192828 @default.
- W4315703068 hasConceptScore W4315703068C2781190966 @default.
- W4315703068 hasConceptScore W4315703068C535046627 @default.
- W4315703068 hasConceptScore W4315703068C61367390 @default.
- W4315703068 hasConceptScore W4315703068C71924100 @default.
- W4315703068 hasConceptScore W4315703068C72563966 @default.
- W4315703068 hasIssue "3" @default.
- W4315703068 hasLocation W43157030681 @default.
- W4315703068 hasLocation W43157030682 @default.
- W4315703068 hasOpenAccess W4315703068 @default.
- W4315703068 hasPrimaryLocation W43157030681 @default.
- W4315703068 hasRelatedWork W122177069 @default.
- W4315703068 hasRelatedWork W1652439388 @default.
- W4315703068 hasRelatedWork W2015876133 @default.
- W4315703068 hasRelatedWork W2021751111 @default.
- W4315703068 hasRelatedWork W2162738516 @default.
- W4315703068 hasRelatedWork W2768013934 @default.
- W4315703068 hasRelatedWork W2768688864 @default.
- W4315703068 hasRelatedWork W2982156914 @default.
- W4315703068 hasRelatedWork W3179582685 @default.
- W4315703068 hasRelatedWork W4226101077 @default.
- W4315703068 hasVolume "41" @default.
- W4315703068 isParatext "false" @default.
- W4315703068 isRetracted "false" @default.
- W4315703068 workType "article" @default.